Premium
Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival
Author(s) -
Nakamaki Tsuyoshi,
Hamano Yasuharu,
Hisatake Junichi,
Yokoyama Akihiro,
Kawakami Keiichiro,
Tomoyasu Shigeru,
Honma Yoshio,
Koeffler Phillip
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04569.x
Subject(s) - cyclin , cyclin a2 , cyclin a , cyclin b , cyclin e , cyclin d , cell cycle , biology , cyclin b1 , cancer research , medicine , andrology , cancer , cyclin dependent kinase 1
Summary. Cyclin A (A2) and cyclin A1 are members of the G 2 cyclins, which are involved in the control of G 2 /M and G 1 /S transitions as well as mitosis. Human cyclin A1 was cloned as an A‐type cyclin that is highly expressed in acute myeloid leukaemia (AML). The clinical significance of these cyclins in myeloid leukaemia remains to be clarified. We investigated the relative levels of these transcripts in 80 patients with de novo AML. Correlations with clinical parameters showed that the initial white blood cell count and serum lactate dehydrogenase levels were inversely associated with cyclin A (A2) mRNA levels ( r = −0·276, P = 0·019) and cyclin A1 mRNA levels ( r = −0·241, P = 0·042) respectively. They were independently associated with increased overall survival [ P = 0·035 for cyclin A (A2) and P = 0·016 for cyclin A1]. Multivariate analysis using Cox's proportional hazard model showed that elevated cyclin A1 mRNA levels contributed significantly to the better prognosis of patients with AML. Furthermore, the analysis of survival probability showed that the group with high levels of both cyclin A (A2) and A1 survived significantly longer than the group with low expression of both these cyclins ( P = 0·002). These data indicate that high expression levels of both cyclin A (A2) and A1 are associated with good prognosis in AML patients.